Actively Recruiting
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Led by Kivu Bioscience Inc. · Updated on 2026-04-16
76
Participants Needed
6
Research Sites
228 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
CONDITIONS
Official Title
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female 18 years of age or older
- No therapy of proven efficacy exists for the tumor
- Pathologically or histologically confirmed advanced or metastatic solid tumor malignancy resistant to standard therapy or without available standard therapy
- Adequate bone marrow, kidney, and liver function
- Measurable disease by RECIST v1.1 criteria
- ECOG performance status of 0 or 1
- Life expectancy of at least 3 months
You will not qualify if you...
- Prior treatment with any antibody-drug conjugate containing a topoisomerase 1 inhibitor
- Previous PTK7-targeted therapy
- Uncontrolled cardiovascular disease
- Active Hepatitis B, Hepatitis C, or HIV infection
- History of interstitial lung disease
- Major surgery, radiation therapy, or systemic anti-cancer treatment within 3 weeks before starting study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Kivu Trial Site
Santa Monica, California, United States, 90403
Actively Recruiting
2
Kivu Trial Site
Camperdown, New South Wales, Australia, 2050
Actively Recruiting
3
Kivu Trial Site
Sydney, New South Wales, Australia
Actively Recruiting
4
Kivu Trial Site
Brisbane, Queensland, Australia
Actively Recruiting
5
Kivu Trial Site
Adelaide, South Australia, Australia
Actively Recruiting
6
Kivu Trial Site
Geelong, Victoria, Australia
Actively Recruiting
Research Team
K
Kivu Bioscience (US)
CONTACT
K
Kivu Bioscience (Australia)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here